Besides its promising anti‐CRC property, the core structure of HNPMI may be further developed to improve EGFR inhibition and treat CRC‐resistant populations, particularly to overcome the resistance mechanism of CRC through the regulation of BCL‐2/BAX and p53 signalling pathways in colon cancer cells. The gene discussed is BCL2; the disease is malignant colon neoplasm.